


Session 2 Wrap-up:
Biomarkers of epigenetic changes
and their applicability to genetic toxicology



Bhaskar Gollapudi, Ph.D
The Dow Chemical Company

Workshop:
**“Genetic Toxicology:
Opportunities to Integrate
New Approaches”**

Apical End Points



Session 2: Biomarkers of epigenetic changes and their applicability to genetic toxicology

- Can biomarkers of epigenetic changes improve/complement the safety assessment process?
 - Yes; more knowledge could lead to better risk assessment decisions.
 - Not ready to do it yet; background variability
- Is there a need to design screening systems to identify “epimutations” with potential trans-generational inheritance?
 - Yes; such “screening” assays are not currently available.
- Can new, less invasive trans-species biomarkers of exposure, susceptibility and effect be identified from accumulated knowledge on epigenetics phenomena?
 - not yet; may be in the future



Dose Response for Epigenetic Biomarkers

